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In this study, we investigated the associations between single-nucleotide polymorphisms in GAB2 (rs2373115),
GSK3B (rs6438552) and SORL1 (rs641120) and Alzheimer’s disease (AD), both alone and in combination with the
APOE*4 allele.
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& INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial neurodegen-
erative disorder that is caused by the interaction of multiple
genetic and environmental factors (1). In the early stages,
Alzheimer’s disease is clinically characterized by short-term
memory impairment, which evolves to widespread cogni-
tive decline and dementia. There is unequivocal evidence
that genetic factors contribute to the pathogenesis of
Alzheimer’s disease, including the sporadic form (2).
Currently, apolipoprotein E is the only well-established
genetic risk factor for sporadic Alzheimer’s disease, and the
APOE*4 allele has been consistently shown to be associated
with an increased risk of Alzheimer’s disease (3,4). There is
little doubt that other – most likely multiple – polymorph-
isms play an important role in the pathophysiology of
Alzheimer’s disease, given that the presence of one or even
two copies of APOE*4 is neither a necessary nor sufficient
condition for developing the disease.
Several new single-nucleotide polymorphisms (SNPs)
associated with on Alzheimer’s disease have recently been
identified in genome-wide association studies, namely
PICALM, CLU, CR1 and SORL1 (5-7). None of these SNPs
can be regarded as etiological factors; rather, they serve as
susceptibility modifiers, i.e., factors with independent or
additive effects in the interactions among several genetic
variants (mostly SNPs) at multiple genomic loci. These
variants may not be deleterious per se, but they may modify
disease outcomes as a result of direct and indirect
interactions with other genetic and environmental factors
(8,9).
Polymorphisms in the SORL1, GAB2 and GSK3B genes
have been shown to be associated with Alzheimer’s disease
in recent studies. Association studies have yielded conflicting
data regarding the role of SORL1 rs641120 in Alzheimer’s
disease (7,10,11-13). A recent study showed that there were
age-dependent differences in SORL1 expression and promo-
ter methylation in an AD cohort, with possible implications
for the disease (14). Likewise, two studies suggested that
there is an association between GAB2 polymorphisms and
AD in Caucasians (15,16), but other studies failed to confirm
this association in European (17) and Asiatic populations
(18,19). Only one study to date has addressed the association
between GSK3B polymorphisms and AD; the results of that
study suggest that rs6438552 has a significant effect on
disease risk (20). Therefore, the objective of the present study
was to determine the effects of GAB2 (rs2373115), GSK3B
(rs6438552) and SORL1 (rs641120) polymorphisms on the risk
for AD and to investigate the interactions of these SNPs with
APOE*4 in a sample of 201 older Brazilian adults.
& MATERIALS AND METHODS
Subjects were recruited from two university-based mem-
ory clinics in Sao Paulo, Brazil. All participants underwent
comprehensive clinical and neuropsychological evaluations.
The diagnosis of probable AD (n = 130, mean age 77¡8.3,
66% females) was established according to the NINCDS-
ADRDA criteria (21). The comparison group included
healthy volunteers (n = 71, mean age 71.8¡6.7; 79% females)
with no signs of cognitive or functional impairment. No
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relatives of AD patients were included in the control group.
No statistically significant differences were observed with
respect to the age distribution or self-reported ethnic
background between the patients and controls, but there
was a greater percentage of females in the control group.
However, we believe that this gender difference should not
negatively affect the findings, as similar results were
obtained in a preliminary analysis of gender-matched
samples.
The GSK3B, GAB2 and SORL1 SNPs were analyzed using
a Real-Time PCR SNP genotyping system (TaqManH Assays
– Applied Biosystems, CA, USA) TaqMan PCR Master Mix
1x, TaqMan SNP genotyping assay 1x, genomic DNA 10 ng/
mL and ultrapure water to a volume of 5 mL were mixed in
each well of an optical plate. Allelic discrimination was
performed using a 7500 Real-Time PCR system (Applied
Biosystems, CA, USA) by comparing the fluorescence levels
before and after amplification (45 cycles of 15 seconds at 95
˚
C and 1 min at 60 C˚). Two SNPs (rs7412 and rs429358) were
evaluated to determine the APOE genotype, as previously
described (22). The real-time PCR reactions were run using
the protocol presented above.
Pearson’s Chi-squared test with simulated p-values was
used to compare the genotype distributions between cases
and controls. The interactions between the GSK3B, GAB2
and SORL1 SNPs and APOE*4 were tested in two ways:
first, each group was stratified into APOE*4-positive and
APOE*4-negative subgroups, and the association between
each SNP and the diagnosis of AD was assessed separately
in each group. In the second step, a binomial logistic
regression model was used to compare the interactions
between APOE*4 and each of the three SNPs in the entire
sample. The statistical analysis was conducted using R
software version 2.12.2.
& RESULTS AND DISCUSSION
Our results are consistent with the well-established role of
the APOE*4 allele as a risk factor for sporadic AD (p,0.0001)
(3, 5, 6, 23-25)(7). Data regarding the genetics of AD in the
Brazilian population remain scarce (26, 27), underscoring the
importance of our findings. We call attention to the positive
association of all the studied SNPs, namely GAB2 rs2373115,
GSK3B rs6438552 and SORL1 rs641120, with AD (Table 1).
The association of the GG genotype of SORL1 with AD
(p= 0.047, OR = 2.07, CI95% [1.17 - 3.68]) was independent of
APOE, and the binomial logistic regression analysis showed
no interaction effect between APOE*4 and any of the SORL1
genotypes (Table 2). We conclude that SORL1 has an
independent role in AD, irrespective of the presence of the
APOE*4 allele.
We found a positive association between the GG genotype
of GAB2 (rs2373115) and the diagnosis of AD (p= 0.021,
OR = 1.8, CI95% [1.01-3.18]). This genotype was associated
with a greater odds ratio (OR) for AD in the APOE*4 carriers
(p= 0.006, OR = 5.08, CI95% [1.45-18.98]). We further used
logistic regression to investigate the interaction between the
APOE*4 and GAB2 polymorphisms (GG vs. non-GG
genotypes, given the small proportion of individuals with
the TT genotype in our sample), and we observed a robust
increase in the effect as a result of the interaction between
GAB2 GG and APOE*4 (p= 0.014, ORinteraction = 7.95,
ORmain = 1.44) (Table 2).
With respect to the association between the GSK3B
polymorphism (rs6438552) and AD diagnosis, we found
that the GG genotype was approximately twice as common
in the AD group (28.8%) than in the controls (13.8%) and
that this genotype had a significant effect on the OR
(p= 0.018, OR = 2.48, CI95% [1.19-5.20]). Interestingly, this
effect was even more pronounced in the absence of APOE*4
Table 1 - Polymorphisms associated with Alzheimer’s disease and sample stratification based on the presence or absence
of the APOE*4 allele.
Gene DbSNP rs ID Risk Allele Freq. Cases Freq. Controls OR (95% CI) p-value
APOE 429358 7412 E4 0.29 0.11 3.33 (1.73-6.63) 0.0001
GAB2 2373115 G 0.83 0.78 1.79 (1.01-3.18) 0.021
APOE*4+ 5.08 (1.45-18.98) 0.006
APOE*4- 1.10 (0.51-2.35) 0.859
GSK3B 6438552 G 0.46 0.44 2.48 (1.19-5.20) 0.018
APOE*4+ 0.76 (0.22-2.88) 0.768
APOE*4- 4.45 (1.47-16.39) 0.003
SORL1 641120 G 0.72 0.60 2.07 (1.17-3.68) 0.047
APOE*4+ 2.02 (0.58-7.31) 0.260
APOE*4- 2.01 (0.94-4.34) 0.054
The OR for APOE was calculated by comparing APOE*4 carriers with non-carriers. The ORs for other genes compared the homozygous risk allele genotype
with the remaining cohort (e.g., GG vs. GT + TT).
Table 2 - Logistic regression analysis of the risk genotype for LOAD in APOE*4 individuals.
Gene DbSNP rs ID Interaction OR interaction OR main effects p-value
GAB2 2373115 APOE*4:GG 7.95 1.44 0.014*
APOE*4:TT { - - -
GSK3B 64384552 APOE*4:GG 1.61 0.65 0.211
APOE*4:AA 1.10 0.19 0.024*
SORL1 641120 APOE*4:GG 1.64 0.49 0.140
APOE*4:AA 5.39 31.03 0.989
*p,0.05. The OR interaction values were obtained by logistic regression evaluating the interaction between APOE*4 and the given genotype. { Because
there were very few individuals who were homozygous for the T allele, this interaction was discarded.
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(p= 0.003, OR = 4.45, CI95% [1.47-16.39]). In contrast, the A
allele was associated with a protective effect, irrespective of
the APOE status (p= 0.018, OR = 0.40, CI95% [0.19-0.84]);
however, the logistic regression analysis showed that
APOE*4-positive carriers of the AA genotype displayed
an increased OR for AD (p= 0.024, ORinteraction = 1.10,
ORmain = 0.19) (Table 2). This finding is noteworthy because
it indicates that the A allele of the GSK3B gene may represent
either a protective factor or a risk factor for AD, depending on
the APOE genotype. We speculate that this dual role may
occur because the rs6438552 polymorphism is intronic and
may affect the transcription and splicing of GSK3B. In fact,
splice variants of GSK3B arising from the AA genotype have
been shown to favor Tau protein hyperphosphorylation,
which is one of the pathological hallmarks of AD (28).
APOE*4 is involved in the abnormal cleavage of the
amyloid-precursor protein (APP), leading to the accumula-
tion of the amyloid-beta peptide, which in turn favors the
hyperphosphorylation of Tau. These pathological changes
ultimately disrupt axonal transport and neuronal viability
(29, 30). GAB2 and GSK3B (rs6438552, AA genotype) have
been shown to increase Tau phosphorylation (15, 28). The
studied GSK3B and GAB2 polymorphisms are located in
intronic regions of these genes and may thus have subtle
effects on transcription, with biological consequences that
are yet to be defined. It is also possible that these SNPs are
in linkage disequilibrium with other polymorphisms that
may contribute to the observed effects. GAB2 is a scaffold-
ing protein with important roles in several growth and
differentiation signaling pathways, including the phosphor-
ylation of kinases that participate in core neurobiological
pathways related to AD (15,16,31,32). GAB2 and presenilin 1
both activate PI3K, leading to the activation of PKB and the
further inactivation of GSK3B (33). Because the inactivation
of GSK3B prevents Tau hyperphosphorylation in neurons
(34), it is reasonable to assume that any decrease in GAB2
expression and/or function would increase Tau phosphor-
ylation (15). Supporting this hypothesis, in vitro studies have
shown that the inhibition of GAB2 expression using siRNA
increases Tau phosphorylation (15).
We conclude that interactions between the GAB2 and
GSK3B polymorphisms and the well-established genetic
factor APOE may modify the overall risk of AD. These
effects are by no means linear or cumulative, given that the
protective effect of a one studied polymorphism (e.g., the
AA genotype of GSK3B) may increase the odds ratio for AD
in the presence of APOE*4. Our results support the
hypothesis that there is no single genetic cause for late-
onset AD; instead, the development of AD depends on the
interaction of several genes, environmental factors and age.
Further evaluation of the interactions between distinct genes
and of the respective implications on neuronal homeostasis
may provide insight into the complex neurobiology of AD.
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